Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to help people with diabetes shed pounds and control blood sugar

NCT ID NCT07400588

Disease control Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new daily pill, aleniglipron, in 58 adults with type 2 diabetes who are overweight or obese. The main goal is to check if the drug is safe and tolerable at different doses. Researchers will also measure weight loss and blood sugar changes. The study is not yet recruiting and is in Phase 2.

Why investors are watching

Structure Therapeutics Inc. is watching this phase 2 trial because it tests aleniglipron, an oral drug for type 2 diabetes in people with obesity or overweight. The trial, run by its subsidiary Gasherbrum Bio, Inc., enrolls only 58 participants and focuses on safety and tolerability at doses up to 240 mg daily. For a small company, this readout is a key checkpoint on whether the drug is safe enough to advance.

If it works: A positive safety and tolerability result could support moving aleniglipron into larger trials, which may strengthen the company's pipeline and attract partnership interest. It would also validate the drug's potential in a large patient population.

If it fails: A failure or delay in this trial could set back the drug's development and hurt the company's prospects, since small companies often depend on a single lead asset. Clinical trials frequently fail, so a negative result is a real possibility.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

58 people

The number who actually took part.

Started

Dec 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed Informed Consent * A diagnosis of T2DM of ≥6 months, * Hemoglobin A1c (HbA1c) ≥6.5% to ≤10% at Screening * Have a BMI ≥27.0 kg/m2 Exclusion Criteria: * Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema. All participants must have a photo fundoscopy, optical coherence tomography, or slit lamp assessment prior to randomization and within the last 12 months to confirm the absence or stable status of diabetic retinopathy and/or macular edema. * Present or planned use of any drug that could interfere with glucose levels * Self-reported change in body weight \>5 kg (11 pounds) within 3 months before screening * Have prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed \>1 year prior to Screening) * Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to Screening, including, but not limited to, mucosal ablation, gastric artery embolization, intragastric balloon, and duodenal-jejunal endoluminal liner

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 2 diabetes mellitus Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESE Obesity Obesity type 2 diabetes mellitus Weight loss

Contacts and locations

Locations

  • Research Site

    Anniston, Alabama, 36207, United States

  • Research Site

    Lake Forest, California, 92630, United States

  • Research Site

    Lomita, California, 90717, United States

  • Research Site

    Hazelwood, Missouri, 63042, United States

  • Research Site

    Columbus, Ohio, 43212, United States

  • Research Site

    Moncks Corner, South Carolina, 29461, United States

  • Research Site

    Chattanooga, Tennessee, 37421, United States

  • Research Site

    Knoxville, Tennessee, 37909, United States

  • Research Site

    Austin, Texas, 78704, United States

  • Research Site

    DeSoto, Texas, 75115, United States

  • Research Site

    Houston, Texas, 77079, United States

  • Research Site

    Mesquite, Texas, 75149, United States

  • Research Site

    San Antonio, Texas, 78215, United States

  • Research Site

    San Antonio, Texas, 78229, United States

  • Research Site

    San Antonio, Texas, 78240, United States

  • Research Site

    Tomball, Texas, 77375, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.